283 related articles for article (PubMed ID: 27452523)
21. Solute carrier family 35 member F2 is indispensable for papillary thyroid carcinoma progression through activation of transforming growth factor-β type I receptor/apoptosis signal-regulating kinase 1/mitogen-activated protein kinase signaling axis.
He J; Jin Y; Zhou M; Li X; Chen W; Wang Y; Gu S; Cao Y; Chu C; Liu X; Zou Q
Cancer Sci; 2018 Mar; 109(3):642-655. PubMed ID: 29274137
[TBL] [Abstract][Full Text] [Related]
22. Interference with TGF-beta1 and -beta3 in tumor stroma lowers tumor interstitial fluid pressure independently of growth in experimental carcinoma.
Lammerts E; Roswall P; Sundberg C; Gotwals PJ; Koteliansky VE; Reed RK; Heldin NE; Rubin K
Int J Cancer; 2002 Dec; 102(5):453-62. PubMed ID: 12432546
[TBL] [Abstract][Full Text] [Related]
23. Cyclin D1, Ret and P27 Expression in Papillary Thyroid Microcarcinoma.
Barić A; Marković V; Eterović D; Bedeković V; Kontić M; Juretić Kuščić L; Pešutić Pisac V; Punda A
Acta Clin Croat; 2017 Mar; 56(1):15-20. PubMed ID: 29120119
[TBL] [Abstract][Full Text] [Related]
24. Transforming growth factor beta(1) selectively inhibits the cyclic AMP-dependent proliferation of primary thyroid epithelial cells by preventing the association of cyclin D3-cdk4 with nuclear p27(kip1).
Depoortere F; Pirson I; Bartek J; Dumont JE; Roger PP
Mol Biol Cell; 2000 Mar; 11(3):1061-76. PubMed ID: 10712520
[TBL] [Abstract][Full Text] [Related]
25. TNF-alpha-induced antiproliferation is not dependent on the autocrine action of TGF-beta 1 in a thyroid cancer cell line.
Pang XP; Yoshimura M; Wang J; Dubinett SM
Lymphokine Cytokine Res; 1994 Apr; 13(2):93-7. PubMed ID: 8061120
[TBL] [Abstract][Full Text] [Related]
26. Pathway- and expression level-dependent effects of oncogenic N-Ras: p27(Kip1) mislocalization by the Ral-GEF pathway and Erk-mediated interference with Smad signaling.
Kfir S; Ehrlich M; Goldshmid A; Liu X; Kloog Y; Henis YI
Mol Cell Biol; 2005 Sep; 25(18):8239-50. PubMed ID: 16135812
[TBL] [Abstract][Full Text] [Related]
27. MicroRNA-96 plays an oncogenic role by targeting FOXO1 and regulating AKT/FOXO1/Bim pathway in papillary thyroid carcinoma cells.
Song HM; Luo Y; Li DF; Wei CK; Hua KY; Song JL; Xu H; Maskey N; Fang L
Int J Clin Exp Pathol; 2015; 8(9):9889-900. PubMed ID: 26617698
[TBL] [Abstract][Full Text] [Related]
28. The BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer.
Riesco-Eizaguirre G; Rodríguez I; De la Vieja A; Costamagna E; Carrasco N; Nistal M; Santisteban P
Cancer Res; 2009 Nov; 69(21):8317-25. PubMed ID: 19861538
[TBL] [Abstract][Full Text] [Related]
29. Clinicopathological significance of loss of p27kip1 expression in papillary thyroid carcinoma.
Kim NY; Kim JH; Pyo JS; Jin Cho W
Int J Biol Markers; 2017 May; 32(2):e255-e259. PubMed ID: 27834461
[TBL] [Abstract][Full Text] [Related]
30. Growth inhibition induced by transforming growth factor-beta1 in human oral squamous cell carcinoma.
Wang X; Sun W; Bai J; Ma L; Yu Y; Geng J; Qi J; Shi Z; Fu S
Mol Biol Rep; 2009 May; 36(5):861-9. PubMed ID: 18418730
[TBL] [Abstract][Full Text] [Related]
31. C-reactive protein promotes acute kidney injury via Smad3-dependent inhibition of CDK2/cyclin E.
Lai W; Tang Y; Huang XR; Ming-Kuen Tang P; Xu A; Szalai AJ; Lou TQ; Lan HY
Kidney Int; 2016 Sep; 90(3):610-26. PubMed ID: 27470679
[TBL] [Abstract][Full Text] [Related]
32. Expression of SMAD proteins, TGF-beta/activin signaling mediators, in human thyroid tissues.
Matsuo SE; Fiore AP; Siguematu SM; Ebina KN; Friguglietti CU; Ferro MC; Kulcsar MA; Kimura ET
Arq Bras Endocrinol Metabol; 2010 Jun; 54(4):406-12. PubMed ID: 20625653
[TBL] [Abstract][Full Text] [Related]
33. A novel human Smad4 mutation is involved in papillary thyroid carcinoma progression.
D'Inzeo S; Nicolussi A; Donini CF; Zani M; Mancini P; Nardi F; Coppa A
Endocr Relat Cancer; 2012 Feb; 19(1):39-55. PubMed ID: 22109972
[TBL] [Abstract][Full Text] [Related]
34. TGF-? regulates the ERK/MAPK pathway independent of the SMAD pathway by repressing miRNA-124 to increase MALAT1 expression in nasopharyngeal carcinoma.
Du M; Chen W; Zhang W; Tian XK; Wang T; Wu J; Gu J; Zhang N; Lu ZW; Qian LX; Fei Q; Wang Y; Peng F; He X; Yin L
Biomed Pharmacother; 2018 Mar; 99():688-696. PubMed ID: 29710466
[TBL] [Abstract][Full Text] [Related]
35. Liuweiwuling tablets attenuate BDL-induced hepatic fibrosis via modulation of TGF-β/Smad and NF-κB signaling pathways.
Liu H; Dong F; Li G; Niu M; Zhang C; Han Y; He L; Yin P; Wang B; Sang X; Li R; Wang J; Bai Z; Xiao X
J Ethnopharmacol; 2018 Jan; 210():232-241. PubMed ID: 28864168
[TBL] [Abstract][Full Text] [Related]
36. MAPK and SHH pathways modulate type 3 deiodinase expression in papillary thyroid carcinoma.
Romitti M; Wajner SM; Ceolin L; Ferreira CV; Ribeiro RV; Rohenkohl HC; Weber Sde S; Lopez PL; Fuziwara CS; Kimura ET; Maia AL
Endocr Relat Cancer; 2016 Mar; 23(3):135-46. PubMed ID: 26825960
[TBL] [Abstract][Full Text] [Related]
37. Punicalagin induces senescent growth arrest in human papillary thyroid carcinoma BCPAP cells via NF-κB signaling pathway.
Cheng X; Yao X; Xu S; Pan J; Yu H; Bao J; Guan H; Lu R; Zhang L
Biomed Pharmacother; 2018 Jul; 103():490-498. PubMed ID: 29677534
[TBL] [Abstract][Full Text] [Related]
38. Beclin 1 is highly expressed in papillary thyroid carcinoma and correlates with lymph node metastasis.
Li X; Xu H; Ma H
Acta Chir Belg; 2013; 113(3):175-81. PubMed ID: 24941712
[TBL] [Abstract][Full Text] [Related]
39. Metastasis-associated MCL1 and P16 copy number alterations dictate resistance to vemurafenib in a BRAFV600E patient-derived papillary thyroid carcinoma preclinical model.
Duquette M; Sadow PM; Husain A; Sims JN; Antonello ZA; Fischer AH; Song C; Castellanos-Rizaldos E; Makrigiorgos GM; Kurebayashi J; Nose V; Van Hummelen P; Bronson RT; Vinco M; Giordano TJ; Dias-Santagata D; Pandolfi PP; Nucera C
Oncotarget; 2015 Dec; 6(40):42445-67. PubMed ID: 26636651
[TBL] [Abstract][Full Text] [Related]
40. Sustained activation of SMAD3/SMAD4 by FOXM1 promotes TGF-β-dependent cancer metastasis.
Xue J; Lin X; Chiu WT; Chen YH; Yu G; Liu M; Feng XH; Sawaya R; Medema RH; Hung MC; Huang S
J Clin Invest; 2014 Feb; 124(2):564-79. PubMed ID: 24382352
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
